This bill amends title 18, United States Code, to require the Bureau of Prisons (BOP) to ensure the widespread availability of opioid antagonist kits , such as naloxone, across all federal correctional facilities. These kits must be maintained in various accessible locations, including medical units, staff breakrooms, and all areas where incarcerated people congregate, and stored appropriately with regular checks for expiration dates. The legislation mandates that incarcerated persons are able to access and administer these kits to others experiencing an overdose, with protection from liability for good-faith administration. It also establishes annual training for both personnel and incarcerated individuals on recognizing overdose symptoms and administering the antagonists. To ensure accountability, the Director of the BOP must document each administration of an opioid antagonist and submit an annual report to Congress detailing compliance, the number of overdoses, and trainings conducted. The bill authorizes appropriations to fund these initiatives, including $6,000,000 for fiscal year 2026.